Core Insights - Veracyte, Inc. is expected to report quarterly earnings on February 25, 2026, with an anticipated EPS of $0.41 and revenue of approximately $135.8 million, driven by its genomic diagnostics tests, Decipher and Afirma [1][5] Financial Performance - In the previous quarter, Veracyte's adjusted EPS was $0.51, exceeding the Zacks Consensus Estimate by 59.38%, and the company has consistently surpassed earnings estimates over the last four quarters with an average surprise of 45.12% [2] - The upcoming Q4 EPS estimate reflects a 13.9% increase from the previous year, with earnings estimates revised upwards by 2% ahead of the announcement [2] Valuation Metrics - Veracyte's financial metrics indicate a high valuation, with a P/E ratio of approximately 94.73, suggesting investors are willing to pay a premium for its earnings [3][5] - The price-to-sales ratio is about 5.82, indicating that investors are paying over five times the company's sales per share [3] - The enterprise value to sales ratio is around 5.27, and the enterprise value to operating cash flow ratio is approximately 24.10 [3] Financial Health - The company's earnings yield is about 1.06%, and it maintains a low debt-to-equity ratio of 0.03, indicating minimal reliance on debt financing [4] - Veracyte has a strong current ratio of 6.23, suggesting robust liquidity and the ability to cover short-term liabilities [4]